[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
[18F]PSMA-1007 PET for biochemical recurrence of prostate cancer, a comparison with [18F]Fluciclovine ; volume:8 ; number:1 ; day:27 ; month:11 ; year:2024 ; pages:1-14 ; date:12.2024
EJNMMI reports ; 8, Heft 1 (27.11.2024), 1-14, 12.2024
- Urheber
-
Loeff, Cato C.
Gemert, Willemijn van
Privé, Bastiaan M.
Oort, Inge M. van
Hermsen, Rick
Somford, Diederik M.
Nagarajah, James
Heijmen, Linda
Janssen, Marcel J. R.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s41824-024-00228-2
- URN
-
urn:nbn:de:101:1-2502112157013.026475227851
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Loeff, Cato C.
- Gemert, Willemijn van
- Privé, Bastiaan M.
- Oort, Inge M. van
- Hermsen, Rick
- Somford, Diederik M.
- Nagarajah, James
- Heijmen, Linda
- Janssen, Marcel J. R.
- SpringerLink (Online service)
Ähnliche Objekte (12)
![Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer](/assets/placeholder/searchResultMediaUnknown.png)
Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
Preclinical comparative study of [18F]AlF-PSMA-11 and [18F]PSMA-1007 in varying PSMA expressing tumors
High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients
Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer
On site production of [18F]PSMA-1007 using different [18F]fluoride activities: practical, technical and economical impact
Heterogeneous uptake of 18F-FDG and 18F-PSMA-1007 PET/CT in lung cancer and lymph node metastasis
68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT
A bicentric retrospective study of the correlation of EAU BCR risk groups with 18F-PSMA-1007 PET/CT detection in prostate cancer biochemical recurrence
A Robust [18F]-PSMA-1007 Radiomics Ensemble Model for Prostate Cancer Risk Stratification
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
Preclinical comparative study of [18F]AlF-PSMA-11 and [18F]PSMA-1007 in varying PSMA expressing tumors
High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients
Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer
On site production of [18F]PSMA-1007 using different [18F]fluoride activities: practical, technical and economical impact
Heterogeneous uptake of 18F-FDG and 18F-PSMA-1007 PET/CT in lung cancer and lymph node metastasis
68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT
A bicentric retrospective study of the correlation of EAU BCR risk groups with 18F-PSMA-1007 PET/CT detection in prostate cancer biochemical recurrence
A Robust [18F]-PSMA-1007 Radiomics Ensemble Model for Prostate Cancer Risk Stratification
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
Diagnostic accuracy of [18F]PSMA-1007 PET/CT in biochemical recurrence of prostate cancer
Preclinical comparative study of [18F]AlF-PSMA-11 and [18F]PSMA-1007 in varying PSMA expressing tumors
High detection rate in [18F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients
Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer
Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007
Parameters predicting [18F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer
On site production of [18F]PSMA-1007 using different [18F]fluoride activities: practical, technical and economical impact
Heterogeneous uptake of 18F-FDG and 18F-PSMA-1007 PET/CT in lung cancer and lymph node metastasis
68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT
A bicentric retrospective study of the correlation of EAU BCR risk groups with 18F-PSMA-1007 PET/CT detection in prostate cancer biochemical recurrence
A Robust [18F]-PSMA-1007 Radiomics Ensemble Model for Prostate Cancer Risk Stratification